Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Sun C, Nierman P, Kendall EK, Cheung J, Gulrajani M, Herman SEM, Pleyer C, Ahn IE, Stetler-Stevenson M, Yuan CM, Maric I, Gaglione EM, Harris HM, Pittaluga S, Wang MH, Patel P, Farooqui MZH, Izumi R, Hamdy A, Covey T, Wiestner A.
Sun C, et al.
Blood. 2020 Jul 2;136(1):93-105. doi: 10.1182/blood.2019003715.
Blood. 2020.
PMID: 32202637
Free PMC article.
Clinical Trial.